publication venue for
- Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study 2021
- Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up. 1-2. 2020
- Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study. 102523-102524. 2020